Ranbaxy Files Three More Antiretrovirals With WHO

Indian drugmaker Ranbaxy has issued a progress report on its filings of HIV/AIDS treatments with the World Health Organisation (WHO). Further to its announcement that it had filed three antiretrovirals under the US government's PEPFAR initiative, the company has now registered the products with the WHO, as pledged a fortnight ago.

Ranbaxy first announced plans to submit its HIV/AIDS treatments for US FDA approval in July 2004, with the first application submitted in October. Meanwhile, the company has pledged to submit its entire antiretrovirals portfolio to the WHO for inclusion to its essential drugs list. The company hopes to complete the majority of both US FDA and WHO filings by March 2005.